Wr-Msra LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$58,997	13
2024	Research	$2,234	10
2023	Research	$94,112	22
2022	Research	$21,409	7

Breakdown

Who paid Research payments · program years 2022–2025

Janssen Research & Development, LLC $92,194 36 payments
AstraZeneca Pharmaceuticals LP $56,729 7 payments
AstraZeneca UK Limited $14,517 2 payments
Lexicon Pharmaceuticals, Inc. $8,262 2 payments
Biohaven Pharmaceutical Holding Company Ltd. $5,049 5 payments

Studies the money was for Research payments · program years 2022–2025

Jjpvc546-Vac546 $47,094 6 payments
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years $45,100 30 payments
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $33,779 4 payments
A Phase II Randomized Openlabel Multicenter Doseranging Study in Adults and Pediatric Individuals 2265 12 years of Age to Assess the Safety Immunogenicity Pharmacokinetics and Pharmacodynamics of AZD7442 a Combination Product of Two Monoclonal Antibodies Tixagevimab and Cilgavimab for Pre-exposure Prophylaxis of COVID19 $14,517 2 payments
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $12,000 1 payment
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis $10,950 2 payments
Relief-Dpn 1 $8,262 2 payments
A Phase 4 Randomized Double-Blind Placebo Controlled Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Subjects with Cardiovascular Contraindication to Triptans High Cardiovascular Risk or Triptan Resistant Subjects $5,049 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.